This week, we’ll be discussing a recent presentation that parsed out differences in disease seen in younger vs older women with breast cancer. We’ll also hear about an update to the NCCN Guidelines for triple-negative breast cancer.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

This week, we’re again discussing findings presented during the Society of Gynecologic Oncology’s (SGO) Virtual 2021 Annual Meeting on Women’s Cancer. We’re hearing from three presenting authors on a number of topics, including maintenance olaparib for newly diagnosed advanced ovarian cancer; maintenance niraparib for platinum-sensitive ovarian cancer; and methods for reducing radiotherapy toxicity in patients with cervical cancer.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

The Society of Gynecologic Oncology’s virtual 2021 Annual Meeting on Women’s Cancer is taking place from March 19 to 25. This week, we’re hearing about findings presented at the meeting in endometrial and ovarian cancers.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

More than a year into the COVID-19 pandemic, researchers are beginning to examine the effects of the virus in the larger health-care sphere. This week, we’ll review a report on an observed increase of breast cancer diagnoses in Italy after pandemic-related screening interruptions. We’ll also discuss two FDA approvals that occurred over the past week for lymphoma and kidney cancer.

Coverage of stories discussed this week on ascopost.com:

Increase in Diagnosis of Node-Positive and Stage III Breast Cancer After Screening Interruption Due to the COVID-19 Pandemic

FDA Grants Accelerated Approval to Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma

FDA Approves Tivozanib for Relapsed or Refractory Advanced Renal Cell Carcinoma

To listen to more podcasts from ASCO, visit asco.org/podcasts.

This week, we’re discussing recent regulatory decisions, ranging from FDA approvals in multiple myeloma and non–small cell lung cancer to the withdrawal of a widely used drug’s indication for small cell lung cancer.

Coverage of stories discussed this week on ascopost.com:

FDA Grants Accelerated Approval to Melphalan Flufenamide for Relapsed or Refractory Multiple Myeloma

FDA Approves Lorlatinib for Metastatic ALK-Positive NSCLC

Pembrolizumab's Indication in Small Cell Lung Cancer Is Withdrawn

To listen to more podcasts from ASCO, visit asco.org/podcasts.

This week, we’re continuing our coverage of results presented at the 2021 Genitourinary Cancers Symposium, focusing on research findings in renal cell carcinoma and bladder cancer.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

This week, we’re continuing our coverage of results presented at the 2021 Genitourinary Cancers Symposium, focusing on research findings in renal cell carcinoma and bladder cancer.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

The 2021 Genitourinary Cancers Symposium took place virtually from February 11 to 13. This week, we’re hearing from three authors of novel research in bladder and kidney cancers.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

This week, we’re again focusing on research presented at the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer Singapore, which was moved to a virtual format and held January 28 to 31, 2021, in light of the COVID-19 pandemic. We’ll hear about findings in mesothelioma, small cell lung cancer, and drug development.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

This week, we’re hearing from two thoracic oncologists on research presented at the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer Singapore, which was moved to a virtual format and held January 28 to 31, 2021, in light of the COVID-19 pandemic.

To listen to more podcasts from ASCO, visit asco.org/podcasts.